136 related articles for article (PubMed ID: 9528860)
21. Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade.
Sabah M; Cummins R; Leader M; Kay E
Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):64-9. PubMed ID: 17536310
[TBL] [Abstract][Full Text] [Related]
22. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas.
Drobnjak M; Latres E; Pollack D; Karpeh M; Dudas M; Woodruff JM; Brennan MF; Cordon-Cardo C
J Natl Cancer Inst; 1994 Apr; 86(7):549-54. PubMed ID: 8133539
[TBL] [Abstract][Full Text] [Related]
23. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.
Folpe AL; Lyles RH; Sprouse JT; Conrad EU; Eary JF
Clin Cancer Res; 2000 Apr; 6(4):1279-87. PubMed ID: 10778952
[TBL] [Abstract][Full Text] [Related]
24. p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
Leach FS; Tokino T; Meltzer P; Burrell M; Oliner JD; Smith S; Hill DE; Sidransky D; Kinzler KW; Vogelstein B
Cancer Res; 1993 May; 53(10 Suppl):2231-4. PubMed ID: 8387391
[TBL] [Abstract][Full Text] [Related]
25. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
26. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of p53 and MDM2 proteins in cervical neoplasia.
Lukás Z; Vojtĕsek B; Anton M; Picksley SM; Kubálek V
Folia Biol (Praha); 1995; 41(3-4):197-9. PubMed ID: 7589715
[TBL] [Abstract][Full Text] [Related]
28. p53 and MDM2 expression in oral squamous cell carcinoma.
Matsumura T; Yoshihama Y; Kimura T; Shintani S; Alcalde RE
Oncology; 1996; 53(4):308-12. PubMed ID: 8692535
[TBL] [Abstract][Full Text] [Related]
29. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps.
Würl P; Bartel F; Meye A; Kappler M; Bache M; Schmidt H; Schönfelder M; Taubert H
Int J Oncol; 2002 May; 20(5):1087-93. PubMed ID: 11956608
[TBL] [Abstract][Full Text] [Related]
30. Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery.
Bode-Lesniewska B; Zhao J; Speel EJ; Biraima AM; Turina M; Komminoth P; Heitz PU
Virchows Arch; 2001 Jan; 438(1):57-65. PubMed ID: 11213836
[TBL] [Abstract][Full Text] [Related]
31. Alterations of G1-S checkpoint in chordoma: the prognostic impact of p53 overexpression.
Naka T; Boltze C; Kuester D; Schulz TO; Schneider-Stock R; Kellner A; Samii A; Herold C; Ostertag H; Roessner A
Cancer; 2005 Sep; 104(6):1255-63. PubMed ID: 16078265
[TBL] [Abstract][Full Text] [Related]
32. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
[TBL] [Abstract][Full Text] [Related]
33. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas.
Ozdemir E; Kakehi Y; Okuno H; Habuchi T; Okada Y; Yoshida O
J Urol; 1997 Jul; 158(1):206-11. PubMed ID: 9186361
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas.
Harlozińska A; Bar J; Montenarh M
Anticancer Res; 2000; 20(2A):1049-56. PubMed ID: 10810396
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of nuclear accumulation of c-myc and mdm2 proteins in synovial sarcoma of the extremities.
Shen J; Scotlandi K; Baldini N; Manara MC; Benini S; Cerisano V; Picci P; Serra M
Oncology; 2000 Apr; 58(3):253-60. PubMed ID: 10765129
[TBL] [Abstract][Full Text] [Related]
36. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
[TBL] [Abstract][Full Text] [Related]
37. p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb.
Gerdes B; Ramaswamy A; Ziegler A; Lang SA; Kersting M; Baumann R; Wild A; Moll R; Rothmund M; Bartsch DK
Ann Surg; 2002 Jan; 235(1):51-9. PubMed ID: 11753042
[TBL] [Abstract][Full Text] [Related]
38. p53 and MDM2 in the development and progression of bladder cancer.
Schmitz-Dräger BJ; Kushima M; Goebell P; Jax TW; Gerharz CD; Bültel H; Schulz WA; Ebert T; Ackermann R
Eur Urol; 1997; 32(4):487-93. PubMed ID: 9412812
[TBL] [Abstract][Full Text] [Related]
39. P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival.
Kasper HU; Schneider-Stock R; Mellin W; Günther T; Roessner A
Pathol Res Pract; 1999; 195(12):815-20. PubMed ID: 10631716
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors and expression of p53 and mdm-2 in uterine sarcomas.
Kim SH; Kim JW; Kim YT; Kim JH; Yoon BS; Ryu HS
Int J Gynaecol Obstet; 2006 Dec; 95(3):272-7. PubMed ID: 16930603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
